相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
4
100.0%
暂无批准数据
- ReAlta Life Sciences appointed Jonathan Rigby, a seasoned biotech executive with a track record of raising over $150 million and leading companies through IPOs and strategic exits, to its Board of Directors. - Rigby brings extensive experience from leadership roles at companies including Zogenix (acquired by UCB Pharma for $2 billion) and SteadyMed Therapeutics (acquired by United Therapeutics for $350 million). - The appointment comes as ReAlta advances pegtarazimod, a dual-mechanism peptide targeting neutrophil-driven inflammation and complement activation for treating conditions like Hypoxic Ischemic Encephalopathy in newborns. - Pegtarazimod has received multiple FDA and EMA designations including Orphan Drug and Fast Track status for Hypoxic Ischemic Encephalopathy and acute Graft vs Host Disease.
- Revolo Biotherapeutics' '1104 targets antigen-presenting cells, shifting the immune system from a pro-inflammatory to a homeostatic state, potentially inducing remission in allergic conditions. - Preclinical and clinical studies validate '1104's mechanism, demonstrating effectiveness in reducing inflammatory cell infiltration and cytokine release in Th2 allergic diseases like eosinophilic esophagitis. - '1104's upstream intervention in the inflammatory cascade offers a more durable disease control and improved patient outcomes compared to traditional therapies targeting downstream effects. - The antigen-agnostic nature of '1104 suggests potential in addressing unmet needs in various allergic diseases beyond EoE, asthma, and atopic dermatitis, such as food allergies.
